Optogenetic Stimulation of Primary Cardiomyocytes Expressing ChR2
نویسندگان
1 1. Department of Photo Healing and Regeneration, Medical Laser Research Center, Yara Institute, ACECR, Tehran, Iran 2. Institutes of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, Iran
2 Institutes of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, Iran
3 School of Life Sciences, Henan University, China
4 Department of Photo Healing and Regeneration, Medical Laser Research Center, Yara Institute, ACECR, Tehran, Iran
5 1. Department of Medical Laser, Medical Laser Reserch Center, Yara Institute, ACECR, Tehran, Iran 2. Research Center for Molecular Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
6 Institutes of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, Iran
doi
31078چکیده
Introduction: Non-clinical cardiovascular drug safety assessment is the main step in the progress of new pharmaceutical products. Cardiac drug safety testing focuses on a delayed rectifier potassium channel block and QT interval prolongation, whereas optogenetics is a powerful technology for modulating the electrophysiological properties of excitable cells.Methods: For this purpose, the blue light-gated ion channel, channelrhodopsin-2 (ChR2), has been introduced into isolated primary neonatal cardiomyocytes via a lentiviral vector. After being subjected to optical stimulation, transmembrane potential and intracellular calcium were assessed.Results: Here, we generated cardiomyocytes expressing ChR2 (light-sensitive protein), that upon optical stimulation, the cardiomyocytes depolarized result from alterations of membrane voltage and intracellular calcium.Conclusion: This cell model was easily adapted to a cell culture system in a laboratory, making this method very attractive for therapeutic research on cardiac optogenetics. DOI: 10.34172/jlms.2021.32
